CTA
SLXP

Chesley Taft & Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Chesley Taft & Associates’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,700
Closed -$734K – 261
2014
Q3 		$734K Sell
4,700
-44,025
-90% -$6.38M 0.08% 157
2014
Q2 		$6.01M Buy
48,725
+16,300
+50% +$1.8M 0.62% 58
2014
Q1 		$3.36M Buy
+32,425
New +$3.32M 0.36% 81

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chesley Taft & Associates's SLXP Position: Q4 2014 in Review

Chesley Taft & Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 4,700 shares — an estimated $734K sold.

Chesley Taft & Associates first reported a position in SLXP in Q1 2014 and held it in 3 quarters. The position peaked at $6.01M in Q2 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Chesley Taft & Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Chesley Taft & Associates sold 4,700 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $734K.
  • Chesley Taft & Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 3 quarters.
  • Chesley Taft & Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $6.01M in Q2 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Chesley Taft & Associates's 13F filing for Q4 2014, filed 12 Jan 2015.